Several DTU staff presented their work at the American Diabetes Association (ADA) conference in Philadelphia, USA, this week.
DTU Director Prof Rury Holman presented a late-breaking poster on Sunday 10th June showing that the apparent rapid increase in glucose levels thought to occur just before diabetes is diagnosed may be an artefact. This has important repercussions for groups seeking a specific metabolic change when diabetes is triggered, which may not exist.
Dr Marcus Lind, one of Prof Holman's collaborators from Lund University in Sweden gave a late-breaking oral presentation on Tuesday 12th June. He described a mathematical analysis of UKPDS data that showed that the substantial contribution of earlier, improved glycaemic (HbAlc) control to subsequent reductions in risk of myocardial infarction and death largely explain the so-called 'legacy effect'.
Senior Researcher Dr Harald Sourij presented a poster with DTU Deputy Director Dr Angelyn Bethel on Saturday 9th June which described the positive impact of the 2008 revised US Food and Drug Administration (FDA) guidance requiring cardiovascular safety assessment for all new diabetes drugs on the design and nature of diabetes clinical outcome studies.
Research Statistician Ruth Coleman presented a poster on Monday 11th June describing an updated version of the UKPDS Risk Engine, a diabetes-specific risk calculator. The revised calculator is more precise and enables clinicians to estimate the risk of cardiovascular disease and death, as well as risks for first as well as second cardiovascular events, in people who have established or newly-diagnosed diabetes.
To read the abstracts for the latter two, see